Spero Therapeutics, Inc. (SPRO) Stock Price & Analysis
Spero Therapeutics, Inc. (SPRO) rose 2.59% to USD 1.19 as of July 25, 2026 at 08:02 UTC, according to Nexqual real-time market data.
SPRO last closed at USD 1.16; the session ranged USD 1.08–1.23 on volume of 11,733,534 shares. Market capitalization is $68.90M, with a 52-week range of USD 1.08–3.08 (NMS). Source: Nexqual, July 25, 2026 at 08:02 UTC.
Key Statistics (as of July 25, 2026 at 08:02 UTC)
| Price | USD 1.19 |
|---|---|
| Change | ▲ 2.59% (up) |
| Previous Close | USD 1.16 |
| Open | USD 1.14 |
| Day Range | USD 1.08 – 1.23 |
| 52-Week Range | USD 1.08 – 3.08 |
| Volume | 11,733,534 shares |
| Market Cap | $68.90M |
| Exchange | NMS |
Technical Analysis (SPRO)
Nexqual's technical model rates SPRO "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 08:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 20.16 (oversold) |
| vs SMA50 | Below (USD 2.32) |
| MACD | -0.32 (negative) |
Analyst Ratings (SPRO)
Wall Street analysts rate SPRO "None" based on 1 analysts, with a mean price target of USD 4 (range USD 4–4), per Nexqual as of July 25, 2026 at 08:02 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 4 |
| High Target | USD 4 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (SPRO)
| Next Earnings Date | 2026-08-11 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.13 vs est -0.25 ▲ beat |
| 2025-06-30 | USD -0.03 vs est -0.38 ▲ beat |
| 2025-03-31 | USD -0.25 vs est -0.44 ▲ beat |
Source: Nexqual, July 25, 2026 at 08:02 UTC.
Financials & Fundamentals (SPRO)
| Total Revenue | $61.19M |
|---|---|
| Revenue Growth (YoY) | -95.60% |
| Gross Margin | +54.61% |
| Operating Margin | -2921.70% |
| Profit Margin | +24.90% |
| ROE | +35.13% |
| Debt / Equity | 4.67 |
| Current Ratio | 10.5 |
| Total Cash | $56.13M |
| Total Debt | $2.47M |
| Free Cash Flow | $13.25M |
Source: Nexqual, July 25, 2026 at 08:02 UTC.
Financial Health Score (SPRO)
Nexqual rates Spero Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 08:02 UTC.
| Growth | Critical — Revenue -54% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $56M cash vs $2M debt, net cash position |
| Cash Flow | Strong — FCF $13M, 28% margin |
| Efficiency | Strong — ROE 35%, ROA 13.0% |
Ownership (SPRO)
| Insider Ownership | +22.46% |
|---|---|
| Institutional Ownership | +16.16% |
| Shares Outstanding | 57.90M |
| Float | 46.38M |
| Short % of Float | +4.41% |
Source: Nexqual, July 25, 2026 at 08:02 UTC.
Leadership (SPRO)
Spero Therapeutics, Inc. is led by Esther P. Rajavelu (age 46), CEO, President, CFO, Chief Business Officer, Treasurer & Director, per Nexqual as of July 25, 2026 at 08:02 UTC.
| CEO, President, CFO, Chief Business Officer, Treasurer & Director | Esther P. Rajavelu (age 46) |
|---|---|
| Chief Operating Officer | Timothy Keutzer (age 57) |
| Senior Vice President of Finance & Business Operations | John Raymond |
Major Backers & Investors (SPRO)
Notable institutional backers of Spero Therapeutics, Inc. include GSK plc, Pfizer Inc, Renaissance Technologies, according to Nexqual as of July 25, 2026 at 08:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GSK plc | 15.87% |
| Pfizer Inc | 4.08% |
| Renaissance Technologies | 2.05% |
| Alphabet Inc. | 1.54% |
| Two Sigma Investments, LP | 1.53% |
| Fidelity | 0.76% |
| Anson Funds Management LP | 0.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.14% |
| Geode Capital | 0.9% |
| BlackRock | 0.75% |
Source: Nexqual, July 25, 2026 at 08:02 UTC.
From Spero Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
- The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
- It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| DTIL | Precision BioSciences, Inc. | USD 7.29 | ▼ 0.41% |
| GOSS | Gossamer Bio, Inc. | USD 0.14 | ▼ 6.21% |
| ALEC | Alector, Inc. | USD 1.48 | ▼ 3.27% |
| BDTX | Black Diamond Therapeutics, Inc | USD 1.76 | ▼ 3.83% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:02 UTC. This page is informational and not investment advice.